Home  »  Companies   »  Why Can-Fite BioPharma Ltd. Stock Might Make Sense...

Why Can-Fite BioPharma Ltd. Stock Might Make Sense If Bought Today

Can-Fite BioPharma Ltd. (AMEX:CANF) traded at $4.74 at close of the session on Tuesday, 01/24/23, made a downward move of -6.32% on its previous day’s price.

Looking at the stock we see that its previous close was $5.06 and the beta (5Y monthly) reads 1.47 with the day’s price range being $4.44 – $5.36. In terms of its 52-week price range, CANF has a high of $12.90 and a low of $4.57. The company’s stock has lost about -30.29% over that past 30 days.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Can-Fite BioPharma Ltd. has a market cap of $15.99 million. Estimates by analysts give the company expected earnings per share (EPS) of -$0.11, with the EPS growth for the year raised at -$0.43 for 2022 and -$0.33 for next year. These figures represent 52.20% and 23.30% growth in EPS for the two years respectively.

The median projection represents growth adding up to -20.00% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2022 is expected to hit $1.01 million, or 18.40% up from figures reported last year.

There have been no upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the CANF stock, short term indicators assign the stock an average of 100% Sell, while medium term indicators assign it an average of 100% Sell. Long term indicators on average place the stock in the category of 100% Sell.

Based on estimates by 2 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 1 have rated the Can-Fite BioPharma Ltd. (CANF) stock as a Hold, while 1 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Overweight and investors could take advantage and scoop up stock of the company.

Looking further, we note the current price level is -18.54% off its SMA20 and -32.81% from its 50-day simple moving average. The RSI (14) is pointing at 32.65 while the volatility over the past week is 13.23% and jumps to 11.64% over the past one month.

Coming back to Can-Fite BioPharma Ltd. (AMEX:CANF), we note that the average 3-month trading volume was 20.58K, while that of the preceding 10-day period stands at 63960.0. Current shares outstanding are 3.14 million.

The institutions hold 1.82%. The data shows that short shares as of Oct 13, 2022, stood at 0.44 million at a short ratio of 9.46. This represents a 1.63% short interest in shares outstanding on Oct 13, 2022. Shares short fall in October from the previous month at 0.47 million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock -22.68% down in year-to-date price movement.

Leave a Comment

Your email address will not be published. Required fields are marked *